Cerebras And Mayo Clinic Announce Foundation Model For Healthcare

JP Morgan’s annual Healthcare Conference is almost becoming an AI event as doctors and AI scientists collaborate to turn petabytes of clinical data into generative AI models and actionable insights. The progress made since Chat GPT’s arrival demonstrates that we are on the precipice of a revolution that will produce cures for many common diseases and save countless lives.

Cerebras Systems (a client of Cambrian-AI Research) announced a new foundation model co-developed with partner The Mayo Clinic, that can identify the best medical therapy for Rheumatoid Arthritis.

Cerebras and Mayo Clinic Apply AI in Healthcare to Predict Efficacy of Drugs

These two institutions have been collaborating for over a year and have produced a new foundation model that can predict the efficacy of drugs to alleviate Rheumatoid Arthritis (RA). Traditionally, RA sufferers resorted to a trial and error approach, with each trial testing a medicine for six months. If it doesn’t help, move on to the next drug and repeat until you hopefully find one that works. Meanwhile, your RA is only getting worse.

The genomic model was trained by combining publicly available human reference genome data with Mayo’s comprehensive patient exome (protein encoding) data. Feeding this data into the Cerebras Wafer Scale Engine, the companies have now trained the first genomic-data-based LLM to predict which medicine will benefit a particular RA patient most. The human reference genome is a digital DNA sequence representing a composite, “idealized” version of the human genome.

Unlike other models trained exclusively on the human reference genome, Mayo’s genomic foundation model is trained on Mayo’s Tapestry dataset incorporating 500 unique patient genomes. The combination of reference and patient genome creates the premier dataset for training a genomic foundation model.

Mayo will continue to refine the model with additional genome data to improve accuracy, but it has already achieved an 87% accuracy in drug prediction. Also, the accuracy of predicting the predisposition of cancer and cardiovascular disease is examined in the chart below.

Where is this heading?

These two companies have only been working together for about a year, and are now turning their expertise and computational power to expanding the foundation model to include support for other areas of medicine.

One can expect that the model will be extended to a variety of tasks, from Pathology to Radiology to Genomics research for Cancer and other drugs.

Combining the power of Cerebras with the data from Mayo is undoubtably helping to create the next generation of medicine.

Disclosures: This article expresses the author’s opinions and should not be taken as advice to purchase from or invest in the companies mentioned. Cambrian-AI Research is fortunate to have many, if not most, semiconductor firms as our clients, including Blaize, BrainChip, Cadence Design, Cerebras, D-Matrix, Eliyan, Esperanto, Flex, GML, Groq, IBM, Intel, Nvidia, Qualcomm Technologies, Si-Five, SiMa.ai, Synopsys, Ventana Microsystems, Tenstorrent and scores of investment clients. We have no investment positions in any of the companies mentioned in this article and do not plan to initiate any in the near future.

 For more information, please visit our website at https://cambrian-AI.com.